Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público

Background: Before the advent of tyrosine kinase inhibitors (TKIs), patients with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL) had a poor prognosis. The association of TKIs to intensive chemotherapy (CT) improved outcome. Aim: To evaluate results of an intensive CT protocol including TKI in a public hospital in Santiago, Chile. Material and Methods: All patients with Ph+ALL diagnosed between January 2010 and February 2019, and who met inclusion criteria for intensive CT, received the Ph+ALL national protocol in association with imatinib and were included in this analysis. Results: Thirty-five patients aged 15 to 59 years received treatment. Complete response (CR) was obtained in 97%. Measurable residual disease (MRD) was negative in 61% (19/31 evaluable cases) during follow-up, and 55% (16/29) were MRD (-) before three months. Relapse was observed in 13 cases. Three patients underwent allogeneic hematopoietic stem cell transplant (HSCT), two in CR1. The overall survival (OS) and event-free survival (EFS) at three years were 52 and 34%, respectively. In patients who achieved MRD negativity before three months, no statistically significant differences in OS (64 and 42% respectively, p = 0.15) or EFS (35 and 32% respectively, p = 0.37) were observed. Conclusions: The prognosis of Ph+ALL improved with the association of imatinib to intensive CT. MRD-negative status before three months in this series was not significantly associated with better outcomes. Our series suggests that the Ph+ALL national protocol associated to TKI is a therapeutic alternative with high CR and aceptable MRD (-) rates.

Saved in:
Bibliographic Details
Main Authors: Benavente,Rafael, Cid,Fernando, Puga,Bárbara, Molina,Javiera, Bass,Francisca, Andrade,Alejandro, Monardes,Virginia, Encina,Andrea, Cabrera,María Elena
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2021
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000901249
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872021000901249
record_format ojs
spelling oai:scielo:S0034-988720210009012492022-03-05Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital públicoBenavente,RafaelCid,FernandoPuga,BárbaraMolina,JavieraBass,FranciscaAndrade,AlejandroMonardes,VirginiaEncina,AndreaCabrera,María Elena Cohort Studies Imatinib Imatinib Mesylate Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma Background: Before the advent of tyrosine kinase inhibitors (TKIs), patients with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL) had a poor prognosis. The association of TKIs to intensive chemotherapy (CT) improved outcome. Aim: To evaluate results of an intensive CT protocol including TKI in a public hospital in Santiago, Chile. Material and Methods: All patients with Ph+ALL diagnosed between January 2010 and February 2019, and who met inclusion criteria for intensive CT, received the Ph+ALL national protocol in association with imatinib and were included in this analysis. Results: Thirty-five patients aged 15 to 59 years received treatment. Complete response (CR) was obtained in 97%. Measurable residual disease (MRD) was negative in 61% (19/31 evaluable cases) during follow-up, and 55% (16/29) were MRD (-) before three months. Relapse was observed in 13 cases. Three patients underwent allogeneic hematopoietic stem cell transplant (HSCT), two in CR1. The overall survival (OS) and event-free survival (EFS) at three years were 52 and 34%, respectively. In patients who achieved MRD negativity before three months, no statistically significant differences in OS (64 and 42% respectively, p = 0.15) or EFS (35 and 32% respectively, p = 0.37) were observed. Conclusions: The prognosis of Ph+ALL improved with the association of imatinib to intensive CT. MRD-negative status before three months in this series was not significantly associated with better outcomes. Our series suggests that the Ph+ALL national protocol associated to TKI is a therapeutic alternative with high CR and aceptable MRD (-) rates.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.149 n.9 20212021-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000901249es10.4067/S0034-98872021000901249
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author Benavente,Rafael
Cid,Fernando
Puga,Bárbara
Molina,Javiera
Bass,Francisca
Andrade,Alejandro
Monardes,Virginia
Encina,Andrea
Cabrera,María Elena
spellingShingle Benavente,Rafael
Cid,Fernando
Puga,Bárbara
Molina,Javiera
Bass,Francisca
Andrade,Alejandro
Monardes,Virginia
Encina,Andrea
Cabrera,María Elena
Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público
author_facet Benavente,Rafael
Cid,Fernando
Puga,Bárbara
Molina,Javiera
Bass,Francisca
Andrade,Alejandro
Monardes,Virginia
Encina,Andrea
Cabrera,María Elena
author_sort Benavente,Rafael
title Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público
title_short Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público
title_full Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público
title_fullStr Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público
title_full_unstemmed Quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, Philadelphia positivo. Experiencia en un hospital público
title_sort quimioterapia intensiva asociada a imatinib en leucemia linfoblástica aguda del adulto, philadelphia positivo. experiencia en un hospital público
description Background: Before the advent of tyrosine kinase inhibitors (TKIs), patients with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ALL) had a poor prognosis. The association of TKIs to intensive chemotherapy (CT) improved outcome. Aim: To evaluate results of an intensive CT protocol including TKI in a public hospital in Santiago, Chile. Material and Methods: All patients with Ph+ALL diagnosed between January 2010 and February 2019, and who met inclusion criteria for intensive CT, received the Ph+ALL national protocol in association with imatinib and were included in this analysis. Results: Thirty-five patients aged 15 to 59 years received treatment. Complete response (CR) was obtained in 97%. Measurable residual disease (MRD) was negative in 61% (19/31 evaluable cases) during follow-up, and 55% (16/29) were MRD (-) before three months. Relapse was observed in 13 cases. Three patients underwent allogeneic hematopoietic stem cell transplant (HSCT), two in CR1. The overall survival (OS) and event-free survival (EFS) at three years were 52 and 34%, respectively. In patients who achieved MRD negativity before three months, no statistically significant differences in OS (64 and 42% respectively, p = 0.15) or EFS (35 and 32% respectively, p = 0.37) were observed. Conclusions: The prognosis of Ph+ALL improved with the association of imatinib to intensive CT. MRD-negative status before three months in this series was not significantly associated with better outcomes. Our series suggests that the Ph+ALL national protocol associated to TKI is a therapeutic alternative with high CR and aceptable MRD (-) rates.
publisher Sociedad Médica de Santiago
publishDate 2021
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000901249
work_keys_str_mv AT benaventerafael quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT cidfernando quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT pugabarbara quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT molinajaviera quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT bassfrancisca quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT andradealejandro quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT monardesvirginia quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT encinaandrea quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
AT cabreramariaelena quimioterapiaintensivaasociadaaimatinibenleucemialinfoblasticaagudadeladultophiladelphiapositivoexperienciaenunhospitalpublico
_version_ 1755988698332135424